{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:25Z","timestamp":1793136985046,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10464-0","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T13:21:37Z","timestamp":1731158497000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines"],"prefix":"10.1007","volume":"30","author":[{"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Todiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Barison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"10464_CR1","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65:1249\u20131254","journal-title":"J Am Coll Cardiol"},{"key":"10464_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ (2018) Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 379:655\u2013668","journal-title":"N Engl J Med"},{"key":"10464_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jacc.2008.11.069","volume":"54","author":"BJ Maron","year":"2009","unstructured":"Maron BJ, Maron MS, Wigle ED, Braunwald E (2009) The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol 54:191\u2013200","journal-title":"J Am Coll Cardiol"},{"key":"10464_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759\u2013769","journal-title":"Lancet"},{"key":"10464_CR5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390:1849\u20131861","journal-title":"N Engl J Med"},{"key":"10464_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.amjmed.2016.09.015","volume":"130","author":"BJ Maron","year":"2017","unstructured":"Maron BJ, Rowin EJ, Maron MS, Braunwald E (2017) Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored\u2026 Until now. Am J Med 130:119\u2013123","journal-title":"Am J Med"},{"key":"10464_CR7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","volume":"35","author":"C O'Mahony","year":"2014","unstructured":"O\u2019Mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35:2010\u20132020","journal-title":"Eur Heart J"},{"issue":"25","key":"10464_CR8","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1016\/j.jacc.2011.10.825","volume":"58","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO et al (2011) 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 58(25):2703\u20132738. https:\/\/doi.org\/10.1016\/j.jacc.2011.10.825","journal-title":"J Am Coll Cardiol"},{"key":"10464_CR9","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA et al (2020) 2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 76:e159\u2013e240","journal-title":"J Am Coll Cardiol"},{"issue":"83","key":"10464_CR10","first-page":"2324","volume":"2024","author":"WC Members","year":"2024","unstructured":"Members WC, Ommen SR, Ho CY et al (2024) AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024(83):2324\u20132405","journal-title":"J Am Coll Cardiol"},{"issue":"35","key":"10464_CR11","first-page":"2733","volume":"2014","author":"PM Elliott","year":"2014","unstructured":"Authors\/Task Force members, Elliott PM, Anastasakis A et al (2014) ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014(35):2733\u20132779","journal-title":"Eur Heart J"},{"key":"10464_CR12","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR et al (2023) 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 44:3503\u20133626","journal-title":"Eur Heart J"},{"key":"10464_CR13","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","volume":"27","author":"CY Ho","year":"2021","unstructured":"Ho CY, Day SM, Axelsson A et al (2021) Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 27:1818\u20131824","journal-title":"Nat Med"},{"issue":"24","key":"10464_CR14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","volume":"342","author":"P Spirito","year":"2000","unstructured":"Spirito P, Bellone P, Harris KM et al (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342(24):1778\u20131785","journal-title":"N Engl J Med"},{"key":"10464_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","volume":"357","author":"PM Elliott","year":"2001","unstructured":"Elliott PM, Gimeno Blanes JR, Mahon NG et al (2001) Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357:420\u2013424","journal-title":"Lancet"},{"issue":"30","key":"10464_CR16","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","volume":"35","author":"C O'Mahony","year":"2014","unstructured":"O\u2019Mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35(30):2010\u20132020","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10464-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:57:18Z","timestamp":1738828638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10464-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["10464"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10464-0","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"31 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM, consultant activity for Attralus, BioMarin Pharmaceutical, Bristol Myers Squibb, Cytokinetics, Eidos, Ionis, Pfizer and Lexicon Pharmaceuticals, Inc. and grants\/contracts from Pfizer, Ionis, Cytokinetics and Attralus; MSM reports consultant activity for Cytokinetics, BioMarin Pharmaceutical Inc., Edgewise, Imbria; the other authors have no relevant conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}